Iterum Therapeutics plc
ITRMDelisted Jun 23, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001659323
Iterum Therapeutics plc was delisted on Jun 23, 2026; its insiders filed their last Form 4 on Nov 20, 2025; 18 institutions reported holding it in 13F filings for Q1 2026, worth $41.3K in total; no superinvestor held it.
13F holders, Q4 2023
Institutional positions in Iterum Therapeutics plc as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 16
- +1 vs. Q3 2023
- Shares held
- 386.6K
- +159.8K (+70.4%) vs. Q3 2023
- Total value
- $761.6K
- +$577.6K (+314.0%) vs. Q3 2023
- New holders
- 3
- 1 more added
- Sold out
- 2
- 3 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ITRM on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 2 | $542 |
| Q1 2026 | 18 | $41.3K |
| Q4 2025 | 20 | $557.9K |
| Q3 2025 | 24 | $904.1K |
| Q2 2025 | 24 | $2.38M |
| Q1 2025 | 20 | $1.38M |
| Q4 2024 | 24 | $2.18M |
| Q3 2024 | 18 | $2.22M |
| Q2 2024 | 15 | $494.7K |
| Q1 2024 | 18 | $1.43M |
| Q4 2023 | 16 | $761.6K |
| Q3 2023 | 15 | $184.0K |
| Q2 2023 | 17 | $393.4K |
| Q1 2023 | 17 | $187.3K |
| Q4 2022 | 23 | $243.7K |
| Q3 2022 | 25 | $575.4K |
| Q2 2022 | 39 | $1.18M |
| Q1 2022 | 41 | $1.80M |
| Q4 2021 | 45 | $2.57M |
| Q3 2021 | 42 | $3.45M |
| Q2 2021 | 45 | $26.0M |
| Q1 2021 | 50 | $11.2M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Iterum Therapeutics plc; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| National Bank of Canada | 2 | $4 | 0.00% | 00.0% | Unchanged |
| HM Payson & Co | 3 | $6 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 12 | $23 | 0.00% | −12−50.0% | Reduced |
| Larson Financial Group LLC | 13 | $26 | 0.00% | 00.0% | Unchanged |
| Ancora Advisors, LLC | 38 | $75 | 0.00% | 00.0% | Unchanged |
| Cypress Capital Management LLC (WY) | 66 | $130 | 0.00% | 00.0% | Unchanged |
| GWM Advisors LLC | 100 | $197 | 0.00% | 00.0% | Unchanged |
| Kelly Financial Services LLC | 120 | $236 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 1,285 | $2.53K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 4,949 | $9.75K | 0.00% | +4,949 | New |
| Morgan Stanley | 5,479 | $10.8K | 0.00% | −8,471−60.7% | Reduced |
| Royal Bank of Canada | 10,000 | $20.0K | 0.00% | +10,000 | New |
| Susquehanna International Group, LLP | 17,533 | $34.5K | 0.00% | −30,123−63.2% | Reduced |
| Renaissance Technologies LLC | 49,922 | $98.0K | 0.00% | +3,000+6.4% | Added |
| New Leaf Venture Partners, L.L.C. | 97,084 | $191.3K | 0.15% | 00.0% | Unchanged |
| Apollon Financial, LLC | 200,000 | $394.0K | 0.16% | +200,000 | New |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −19,566−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −22−100.0% | Sold out |